Clinical Trial Update: Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab in combination with irinotecan and carboplatin for recurrent malignant glioma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Annick Desjardins | Conditions: Malignant Glioma | Phase 2 | Status: COMPLETED | Results posted: 2013-09-04